Catalyst · regulatory decision
FDA action on MACE risk reduction indication based on SELECT trial.
Expected: Jan 1, 2024 – Dec 31, 2024
Catalyst details
- Type
- regulatory decision
- Status
- completed
- Date precision
- window
- Confidence
- regulator calendar
- Asset
- Semaglutide
- Company
- Novo Nordisk
- Actual date
- Mar 8, 2024
Source wording
“FDA action on MACE risk reduction indication based on SELECT trial.”
Sources
- regulatoryprimary record
FDA approves Wegovy (semaglutide) for chronic weight management
U.S. Food and Drug Administration · FDA News Release · Jun 4, 2021